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Abstract
Background: Protein kinase C interacting protein (PKCI/HINT1) is a small protein belonging to
the histidine triad (HIT) family proteins. Its brain immunoreactivity is located in neurons and
neuronal processes. PKCI/HINT1 gene knockout (KO) mice display hyper-locomotion in response
to D-amphetamine which is considered a positive symptom of schizophrenia in animal models.
Postmortem studies identified PKCI/HINT1 as a candidate molecule for schizophrenia and bipolar
disorder. We investigated the hypothesis that the PKCI/HINT1 gene may play an important role in
regulating mood function in the CNS. We submitted PKCI/HINT1 KO mice and their wild type
(WT) littermates to behavioral tests used to study anti-depressant, anxiety like behaviors, and goal-
oriented behavior. Additionally, as many mood disorders coincide with modifications of
hypothalamic-pituitary-adrenal (HPA) axis function, we assessed the HPA activity through
measurement of plasma corticosterone levels.
Results: Compared to the WT controls, KO mice exhibited less immobility in the forced swim
(FST) and the tail suspension (TST) tests. Activity in the TST tended to be attenuated by acute
treatment with valproate at 300 mg/kg in KO mice. The PKCI/HINT1 KO mice presented less
thigmotaxis in the Morris water maze and spent progressively more time in the lit compartment in
the light/dark test. In a place navigation task, KO mice exhibited enhanced acquisition and retention.
Furthermore, the afternoon basal plasma corticosterone level in PKCI/HINT1 KO mice was
significantly higher than in the WT.
Conclusion: PKCI/HINT1 KO mice displayed a phenotype of behavioral and endocrine features
which indicate changes of mood function, including anxiolytic-like and anti-depressant like
behaviors, in conjunction with an elevated corticosterone level in plasma. These results suggest that
the PKCI/HINT 1 gene could be important for the mood regulation function in the CNS.
Background
Mood disorders, including depressive and bipolar disor-
ders, are severe, chronic and often life-threatening ill-
nesses with symptoms manifested at the psychological,
behavioral, and physiological levels. Their etiology is not
precisely understood but is believed to be multifactorial,
involving heredity, changes in neurotransmitter levels,
altered neuroendocrine function, and psychosocial factors
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[1]. In the laboratory, the biological study of mood disor-
ders benefits from standardized animal behavioral tests
that have been validated for their predictive validity for
antidepressant and anxiolytic drugs. These tests are cur-
rently considered major tools for studying the function of
targeted mutation in transgenic mice [2]. The forced swim
(FST) and tail suspension (TST) were developed to evalu-
ate anti-depressant like effects of drugs [3,4]. In geneti-
cally modified mice, anti-depressant-like behavior is
modeled as a decreased immobility in the FST and the TST
[5,6]. In comparison, the cyclic episodes of depression
and mania characteristic of bipolar disorder is more diffi-
cult to model in a single animal. Therefore facets of bipo-
lar disorder are commonly studied separately using
distinct models for depression and mania [7,8]. However,
in contrast to current models of depression-related behav-
ior mentioned above, there is no specific model for stud-
ying mania-like behavior. Nonetheless, some paradigms
are used for their similarity with clinical observations and
are validated through their response to classical mood sta-
bilizing drugs. For example, increased energy or restless-
ness can be modeled by the hyperactivity induced by
psychostimulants, or as a response to a stressful situation
and monitored in an open field test, and in the test related
to a stressful situation [7]. Also, poor judgment leading to
risk-taking can be tested as a mirror image of most tests for
anxiety-like behavior [9]. Thus the light/dark paradigm
based on the mice's natural avoidance of bright spaces is
widely used to measure anxiety-like behavior in mutant
mice [10]; animals that spend less time in the lit compart-
ment are considered to exhibit anxiety-related behavior
[11,12]. Similarly, open spaces in the open-field and in
the Morris water maze serve as another index of anxiety-
like behavior based on the propensity of small rodents to
avoid open areas. In these paradigms anxiety-related
behavior is assessed through the measure of thigmotaxis
or wall-seeking behavior [13]. Furthermore, genetic vul-
nerability to mania is believed to be expressed behavio-
rally as excessive goal pursuit [14] which can be modeled
using goal-oriented behavioral tests.
Pharmacological validation of mania-like behavior can be
performed with valproate, a mood stabilizing agent used
clinically to treat acute mania [15], which also decreases
the phenotype of hyperactivity in the mouse model of
mania [16].
In terms of endocrinology, mood disorders coincide with
modifications of hypothalamic-pituitary-adrenal (HPA)
axis function which can be assessed by measuring plasma
glucocorticoid levels. A high plasma cortisol level is con-
sidered an endocrine feature of depression and bipolar
disorder in patients [17-19]. Manic episodes have been
shown to be preceded by increases in plasma cortisol
level. Therefore HPA axis dysfunction was proposed as a
potential trait marker in bipolar disorder, possibly indica-
tive of the core pathophysiologic process in the illness
[20]. In rodents, behavioral responses described as
depression-like and anxiety-related coincide with
increases in the level of plasma corticosterone [21-24]. In
contrast, reduced depression-like and less anxiety-related
behaviors are associated with a lowered level of plasma
corticosterone [25,26]. In the animal models, therefore,
increases in plasma corticosterone levels might argue for
face validity at the endocrine level.
PKCI/HINT1 is a member of the HIT protein family, char-
acterized by the presence of a HIT (HisXHisXHis, where X
is a hydrophobic amino acid) sequence motif [27,28].
Although the general function of PKCI/HINT1, as well as
its presumably more specialized role in the central nerv-
ous system, is not known, results from human postmortem
analysis and mice behavioral and anatomical studies sug-
gest that it might be involved in the pathophysiology of
certain mental disorders. PKCI/HINT1 was identified as a
candidate molecule in the neuropathology of schizophre-
nia when its gene expression was shown to be decreased
via microarray analysis in the prefrontal cortex of schizo-
phrenic patients [29,30], as subsequently validated by
real-time quantitative polymerase chain reaction [31].
PKCI/HINT1 was also recognized as a gene candidate in
the neuropathology of bipolar disorder when its
decreased expression in the dorsolateral prefrontal cortex
was confirmed in a meta-analysis of 12 microarray studies
of bipolar disorder [32]. We recently showed that,
although they do not show any spontaneous hyperactivity
in the open field test, PKCI/HINT1 KO mice present
higher locomotor and stereotypic responses to the psy-
chostimulant D-amphetamine than WT controls. These
are considered positive symptoms in animal models for
schizophrenia [33]. Our study of the brain's distribution
of PKCI/HINT1 revealed that its immunoreactivity is pri-
marily located in neurons and neuronal processes of par-
valbumin positive neurons in cerebral cortex and limbic
system [34]. These regions are anatomically related to
mood disorders [35-37].
Based on the findings from postmortem studies, PKCI/
HINT1 KO mice behavioral observations, and immunocy-
tochemical localization of the PKCI/HINT1 in the brain,
we hypothesize that the PKCI/HINT1 protein might be
involved in specific neuropsychological functions such
that its absence would lead to significant behavioral and
endocrine phenotypes associated with mood dysfunction.
Accordingly, we attempted to test this hypothesis using
PKCI/HINT1 KO mice. We assessed behavioral pheno-
types that may be characteristic of mood disorders by
using the forced swim and tail suspension tests, which are
used to model antidepressant-like behavior. We also
looked at the involvement of PKCI/HINT1 in the light/BMC Neuroscience 2009, 10:132 http://www.biomedcentral.com/1471-2202/10/132
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dark paradigm and in thigmotaxis as indices of anxiety-
related behavior, and we used the Morris water maze test
for place navigation learning to assess goal-oriented
behavior. In order to search for associated endocrine rele-
vance, we assessed the HPA axis activity through the meas-
urement of plasma corticosterone levels.
Pharmacologically, we examined the effect of valproate
on the activity of the animals submitted to the tail suspen-
sion test.
Results
PKCI/HINT1 KO mice exhibited less immobility than their 
WT littermates in the forced swim and the tail suspension 
tests
Immobility in the forced swim test is shown in Figure 1,
where the PKCI/HINT1 KO mice were 2 times less immo-
bile than their WT littermates at every stage of the test
from day 1 to each of the trials in the four time periods of
the second day, F(1,145) = 145.55, P < 0.0001 for genotype
in a two-way ANOVA of trials × genotype. Immobility
time on day 1 represented 43% of the total time in the WT
mice and 23% in the KO. When considering the four trials
of the second day both WT and KO mice displayed
increases in immobility over the trials, F(4,145) = 12.12, P <
0.0001 for trials effect, with similar slopes, F(1,151) = 0.519,
P < 0.472. WT mice displayed a significantly progressive
increase in immobility over the number of trials as com-
pared with day 1; on the last trial, immobility time
reached 85% of total time. KO mice showed less increase
in immobility compared to WT on the last trial, with
immobility reaching 42% of total time.
In the tail suspension test, WT and KO mice displayed sig-
nificant score differences over the 10 min test period as
shown in Figure 2. In Figure 2A, the overall immobility
time of WT mice was of 83% of the total time; PKCI/
HINT1 KO mice were 30% less immobile with an immo-
bility time of 58% of the total time. Overall KO mice
scores consisted of a 4 times higher frequency of small
movements (Figure 2B) and 6 times higher frequency of
strong movements of body jerks and jumps than the WT
(Figure 2C). Time course analysis reveals an effect of time
for the three parameters in a two-way ANOVA genotype ×
time, immobility F(9,240) = 4.34, P < 0.0001, small move-
ments F(9,240) = 2.70, P = 0.0053 and strong movements
F(9,240) = 9.54, P < 0.0001 (Figures 2D, 2E, 2F). In figure
2D, KO mice immobility can be viewed in two phases:
one phase was the first minute of the test where initial
immobility time is 25% of total time, and the second
phase was a 9 min steady state where immobility
increased to 63% of total time. Two similar phases can be
observed with the production of small and strong move-
ments, as illustrated in Figure 2E and Figure 2F, respec-
tively. KO and WT mice behavior patterns were different,
as indicated by the genotype effects: F(1,240) = 102.54, P <
0.0001 for immobility, F(1,240) = 93.57, P < 0.0001 for
small movements, and F(1,240) = 57.01, P < 0.0001 for
strong movements. Indeed, during the 10 min test WT
mice exhibited a steady state behavior for each of the three
parameters of the test (immobility, small and strong
movements). KO mice demonstrated less immobility
characterized by more energetic movements as illustrated
by the overall measurement and the persistence of bouts
of strong movements at 5 min of the test.
Acute valproic acid decreases the activity of KO mice in 
the tail suspension test
Figure 3 represents the effect of acute valproate treatment
on total movements. A two-way ANOVA of genotype ×
treatment shows a genotype effect F(1,33) = 26.73, P <
0.0001 and no treatment effect F(2,33) = 2.33, P = 0.1135.
Following saline injection, PKCI/HINT1 KO mice dis-
played 2.3 times more movements than the WT. Valproate
(100 mg/kg or 300 mg/kg), when compared with saline
treatment, did not induce any significant change in the
number of movements in WT mice. PKCI/HINT1 KO mice
pretreatment with valproate (300 mg/kg) revealed a statis-
tically insignificant trend towards movement attenuation
as compared with saline treatment. The number of move-
ments reached was comparable to WT controls.
In the light/dark test PKCI/HINT1 KO mice spent 
progressively more time in the light compartment than the 
WT
Scores of the PKCI/HINT1 KO mice and their WT litterma-
tes in the light/dark test are presented in Figure 4 as a time
course of the time spent in the lit compartment during the
light-dark test. During the first 5 min of the test there was
no difference between WT and KO mice; WT mice spent
Porsolt's forced swim test Figure 1
Porsolt's forced swim test. Scores of immobility in sec 
are represented for the last 4 min of each trial. ^^ P < 0.01, 
^^^P < 0.0001 vs. Day1; * P < 0.05, *** P < 0.0001 WT vs. 
KO, Bonferroni post hoc. WT n = 15, KO n = 16.
D1 Period 1 Period 2 Period 3 Period 4
0
25
50
75
100
125
150
175
200
225
250
WT
^^
^^^ ^^^
^^^
 ^^
***
*
***
*** ***
Day 1 Day 2
KO
I
m
m
o
b
i
l
i
t
y
 
t
i
m
e
 
(
s
e
c
)BMC Neuroscience 2009, 10:132 http://www.biomedcentral.com/1471-2202/10/132
Page 4 of 14
(page number not for citation purposes)
Tail suspension test monitored for 10 min Figure 2
Tail suspension test monitored for 10 min. Sum of total scores of immobility are reported in sec (2A), small (2B) and 
strong movements (2C) in arbitrary units (AU). Time course of immobility (2D), small movements of running and body tor-
sions (2E) and strong movements of body jerks and jumps (2F) are reported in bins of 1 min. *** P < 0.001 WT vs. KO, Stu-
dents t-test; ^ P < 0.05, ^^ P < 0.01, ^^^ P <0.0001 WT vs. KO, Bonferroni post hoc; oo P < 0.01, ooo P < 0.001 vs. each 
different time point, Bonferroni post hoc; o P < 0.05 vs.7, 8, 9, 10 min, Bonferroni post hoc. WT n = 13, KO n = 13.
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47% of the time in the lit compartment and PKCI/HINT1
KO mice spent 42%. Curve analysis showed different
slopes for WT and KO, F(1,91) = 5.41 P = 0.02. WT animals
displayed a slight decrease in the time spent in lit com-
partment that reaches 41% at the end of the test with a
negative linear regression coefficient of -0.37 not signifi-
cantly different from zero, F(1,43) = 0.32 P = 0.57. PKCI/
HINT1 KO mice spent progressively more time in the lit
compartment to reach 75% at 25 min; this is illustrated by
a positive linear regression coefficient of 1.68 which is sig-
nificantly different from zero, F(1,48) = 7.93 P = 0.007. KO
mice exhibited a significant progressive preference for the
lit compartment.
Place navigation performance is enhanced in the PKCI/
HINT1 KO mice
The beacon cued learning test of the Morris water maze
was used as a control experiment to assess ability to learn
to swim to a cued goal that relies on intact eyesight, swim-
ming ability, basic strategies of swimming away from the
wall, climbing to the platform and motivation to escape
from the water [38]. Performances, shown in Figure 5,
were identical in WT and KO mice. Both animals learned
to swim and escape to the platform with similar latencies.
The Morris water maze version of a place navigation cog-
nitive test depends on the function of the associative pari-
etal cortex [39]. This test was chosen in relation to the
anatomical localization of the decrease in PKCI/HINT1 in
the dorsolateral prefrontal cortex of bipolar patients [32].
Performances of PKCI/HINT1 KO mice and WT litterma-
tes are presented in Figure 6. Latency to reach the platform
within the 2 min test, plotted as a function of trials in Fig-
ure 6A, shows a trials effect, F(6,126) = 7.78, P < 0.0001 in a
two-way ANOVA trials × genotype. This implies that both
WT and KO animals underwent acquisition (learning).
Valproic acid effect on movements in the tail suspension test Figure 3
Valproic acid effect on movements in the tail suspen-
sion test. Small and strong movements in AU were meas-
ured 30 min following ip treatment with saline and valproic 
acid (VPA) 100 mg/kg and 300 mg/kg. Treatments were dis-
pensed at 15 days intervals. ** P < 0.01 WT vs. KO, Bonfer-
roni post hoc. WT n = 6, KO n = 8.
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Time course of the light/dark test Figure 4
Time course of the light/dark test. Percent time spent in 
the lit compartment is represented within 5 min bins over 
the 25 min test period. Linear regressions: WT: y = -0.37 x + 
52.6 (R2 = 0.49); KO: y = 1.66 x + 36.98 (R2 = 0.94). WT n = 
9, KO n = 10.
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Cued learning Figure 5
Cued learning. Learning performances in 16 trials of 2 min 
were assessed as latency to reach the beacon platform in the 
Morris water maze and are represented in 4 blocks of 4 tri-
als. Linear regression curve of learning pattern for WT: y = -
12.23 x + 86 and for KO: y = -15 x + 93 for KO. * at least P 
< 0.05 vs. each other trial for WT; ^^ at least P < 0.01 vs. 
each other trial for KO, Bonferroni post hoc. WT n = 7-10, 
KO n = 7-11.
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Place navigation learning using proximal landmarks and memory Figure 6
Place navigation learning using proximal landmarks and memory. 6A - Acquisition. Learning performances in 28 
trials of 2 min were measured as latency to reach the platform in sec, and are represented in blocks of 4 trials. ^P <0.05, ^^P < 
0.01, ^^^P <0.001 vs. first block; * P < 0.05, **P < 0.01 WT vs. KO, Bonferroni post hoc. 6B - Probe test. Retention was 
assessed as the number of the crossings of the platform area in a 1 min test before and after acquisition. ^^^ P < 0.001 vs. 
before acquisition; ** P < 0.01 WT vs. KO, Bonferroni post hoc. Thigmotaxis and floating time were measured during the 
acquisition phase and the subsequent probe test. Average thigmotaxis time in sec (6C). ** P < 0.01, WT vs KO, Student's t-
test. Thigmotaxis time course as percent of total time (6D). ^ P < 0.05, ^^P < 0.01 vs. trial 1, Bonferroni post hoc. Average 
floating time in sec (6E). **P < 0.01 WT vs KO, Mann-Whitney. Floating time course as percent of total time (6F). WT n = 10, 
KO n = 10.
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Initial latencies to reach the platform on the first trial were
not different between WT and KO. However, a genotype
effect, F(1,126) = 34.38 P < 0.0001, accounts for differences
in the learning pattern on the trials. Significant acquisi-
tion was demonstrated in the last block of trials by WT
mice with a latency of 62 sec, while PKCI/HINT1 KO mice
displayed faster learning with a significantly lower latency
of 55 sec as early as the third block of the trials. KO mice
displayed significantly better learning, as attested by a 2.6
times lower latency to reach the platform on the last block
of trials compared to the WT.
Retention (memory), shown in Figure 6B, was determined
during a 60 sec probe test by counting the number of
crossings of the platform area, both before training and 24
h following the last acquisition trial. Both WT and KO ani-
mals displayed an increase in scores after acquisition with
trials effect, F(1,34) = 15.67 P = 0.0004, in a two-way
ANOVA trials × genotype. Animals displayed differences
in performances with a genotype effect, F(1,34) = 4.97 P =
0.0324. Before training, both WT and KO mice scores
were near zero. After acquisition, WT animals crossed the
platform area once whereas PKCI/HINT1 KO mice
showed clear retention by crossing the platform area at
least two times, which is considered criterion performance
[40].
Non cognitive factors are associated with learning and 
retention performances
Non cognitive factors like thigmotaxis and floating are
often associated with performance in the Morris water
maze [41]. Thigmotaxis time measured when mice swam
at a distance within 10 cm of the wall of the pool is an
indicator of open space anxiety-related behavior [42]. Fig-
ure 6C represents the overall thigmotaxis time during the
acquisition phase and the probe test where the PKCI/
HINT1 KO mice exhibited significantly 2.8 times less thig-
motaxis than WT mice. Evolution of thigmotaxis with tri-
als shown in Figure 6D reveals habituation during the
acquisition phase with a trials effect, F(7,144)= 4.28, P =
0.0003, and a genotype effect, F(1,144) = 40.09, P < 0.0001,
in a two-way ANOVA trials × genotype. When compared
with trial 1, thigmotaxis significantly decreased at trials 5
and 4 for WT and KO respectively.
Floating time (i.e., immobility) was measured during the
acquisition phase and the probe test. Figure 6E shows that
overall floating scores for KO mice were significantly
lower than WT by 5.3 times. The graph representing float-
ing time as a function of trials in Figure 6F shows a geno-
type effect, F(1,144) = 39.03, P < 0.0001, in a two-way
ANOVA trials × genotype, but no significant trials effect
F(7,144) = 0.19 P = 0. 9879, the floating time for KO mice
was lower than WT mice in every block. Thus WT and KO
animals did not exhibit any change in floating time over
the trials.
PKCI/HINT1 KO mice basal hypothalamic-pituitary-
adrenal axis activity is higher than in wild type mice
As shown in Figure 7, basal plasma corticosterone level in
wild type animals was 102.5 ng/ml in the morning and
increased by 79% to reach a value of 183.3 ng/ml in the
afternoon. The acute stress of the tail suspension test
induced an additional increase compared to the afternoon
basal level. The same pattern of morning to afternoon var-
iation and increased corticosterone levels after the stressor
were observed in the PKCI/HINT1 KO mice, F(2,84) = 49.8,
P < 0.0001, for condition in a 2-way ANOVA condition ×
genotype. Additionally, KO mice displayed an afternoon
baseline level that was 30% higher than the WT mice,
F(1,84) = 5.27, P = 0.0243 for genotype in a 2-way ANOVA
condition × genotype. Immediately following a tail sus-
pension test, WT and KO mice displayed comparable
responses to stress, with increased of corticosterone levels
reaching 282 ng/ml and 332 ng/ml respectively.
Discussion
We searched for a distinctive phenotype of PKCI/HINT1
KO mice in order to determine the putative role of the
PKCI/HINT1 protein in brain function and in particular
its involvement in mood regulation.
Plasma corticosterone levelsin PKCI/HINT1 KO mice and  their WT controls Figure 7
Plasma corticosterone levelsin PKCI/HINT1 KO 
mice and their WT controls. Plasma corticosterone lev-
els (ng/ml of plasma) were determined for three conditions, 
as basal in the morning (BSL-AM), basal in the afternoon 
(BSL-PM), and following a 6 min tail suspension test per-
formed in the afternoon (TST). * P < 0.05 WT vs. KO; (*) P < 
0.05, (***) P < 0.001 vs. morning baseline; (^^) P < 0.01 vs. 
afternoon baseline, Bonferroni post hoc. WT n = 15, KO n = 
15.
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In order to assess antidepressant-like behavior, we used
two standard tests, the Porsolt's forced swim test and the
tail suspension test. In both tests PKCI/HINT1 KO mice
exhibited less immobility than their WT littermates. This
phenotype was further confirmed in the Morris water
maze where KO animals exhibited less floating time than
the WT. Decreased immobility in the FST and the TST may
be due to an antidepressant or a general stimulatory effect,
as pointed out by pharmacological studies; antidepressant
effects are manifested in attempts to escape, while stimu-
lants lead to motor stimulation that can be measured as
an increase in spontaneous activity in the open field test
[3,43]. As PKCI/HINT1 KO mice did not display sponta-
neous hyperactivity in the open field test [33], the
decreases in immobility presented here are likely due to
persistence in attempts to escape rather than generalized
motor stimulation. This is exemplified in the persistence
of small and strong movements in the TST.
Treatment with the mood stabilizer valproate at 300 mg/
kg tended to attenuate the movements of KO mice. How-
ever a non-significant trend of decreased movements in
the WT mice treated with 100 or 300 mg/kg suggests a
possible sedative effect of the drug in stead of mood regu-
lation, which could be specifically assessed in the open
field test.
We used the light-dark test based on the mouse's natural
preference for the dark and avoidance of bright spaces to
assess anxiety-related behavior. In the first 5 min corre-
sponding to the classical version of the test that assesses
light/dark preference, there was no difference between KO
and the WT controls, as both animal types spent an aver-
age of 45% of the total time in the lit compartment. A sim-
ilar slight preference for the dark compartment was
reported in mice from the C57Bl and 129/SveV strains
that were naïve to any test when submitted to the light/
dark box [44]. The time course of the 25 min test showed
that time spent in the lit compartment increased progres-
sively in PKCI/HINT1 KO mice, so that in the last 5 min
KO mice spent significantly more time in the lit compart-
ment than WT mice. This phenotype could not be totally
attributed to an anxiolytic effect and the 25 min light/dark
test would require pharmacological validation to be
related to anxiety. An alternative explanation would be
that, by showing a preference for the naturally aversive
properties of the light spaces, the KO mice were exhibiting
a risk-taking behavior. Additionally, PKCI/HINT1 KO
mice in the Morris water maze place navigation task dis-
played significantly less thigmotaxis than the WT mice,
showing less anxiety behavior related to open space. In
that case, thigmotaxis might have some influence on the
learning performances. However, as in the beacon cued
learning test with a visible escape WT and KO mice
showed similar learning performances, it is probable that
in our mice thigmotaxis in the water maze is related to the
higher anxiogenic conditions of non visible escape in the
place navigation task.
In several experiments presented here, habituation was an
important factor, such as habituation to an aversive or
novel stimulus. Thus some of the results implicated here
may imply that there is accelerated habituation in PKCI/
HINT1 KO mice, at least to the anxiety-provoking aspects
of the experimental environments. Perhaps due to this dif-
ference, PKCI/HINT1 KO mice exhibited a faster acquisi-
tion in the place navigation learning task, and
consequently better retention.
By contrast in the modified version of the FST, repeated
testing increased immobility to a greater degree in WT
mice than in PKCI/HINT1 KO mice. On the second day of
FST testing, an increased immobility was observed in WT
controls compared to the first trial, while PKCI/HINT1
KO mice remained as active as they were during the first
exposure day, not demonstrating increased immobility
until the last test of the second day. In the FST paradigm,
increased immobility can potentially be influenced by
several factors. Although generally considered to measure
behavioral despair in relation to the effect of anti-depres-
sant drugs [5] it can also reflect learned habituation to an
environment that has become familiar to the animal
thereby including a memory component on the second
exposure. Lastly, it could reflect a relatively successful cop-
ing strategy that employs energy-conserving behavior and
may confer a survival advantage (for review [45]).
As KO mice displayed higher performances in the learning
task of place navigation, it is less likely that less learning
capacity is responsible for their delayed increased immo-
bility in the FST. Yet, PKCI/HINT1 KO mice's persistent
struggling in both FST and TST could be related to less
coping behavior [45], and thus express excessive goal pur-
suit as previously suggested in the FST [46]. In the same
sense, it is also noteworthy that in the goal-directed task
of cocaine-induced conditioned place preference, PKCI/
HINT1 KO mice displayed enhanced performances as
compared with WT (manuscript in preparation).
Thus the current behavioral data indicate that PKCI/
HINT1 has an important influence on depression and
open space-anxiety related tests. Moreover, PKCI/HINT1
plays an important role in learning and exploration in the
place navigation water maze and the development of pref-
erence for aversive environment in the 25 min version of
the light/dark test.
Parallel to the behavioral phenotypes, we assessed the
activity of the HPA axis via the measurement of plasma
corticosterone levels. Noticeably, in the same time frameBMC Neuroscience 2009, 10:132 http://www.biomedcentral.com/1471-2202/10/132
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corresponding to the behavioral experiments, PKCI/
HINT1 KO mice displayed a higher afternoon basal
plasma corticosterone level than the WT controls.
However, the elevated level of corticosterone measured in
PKCI/HINT1 KO mice is actually the opposite of what
would be expected given the observed behavioral changes.
Antidepressant in FST and TST and anxiolytic-like behav-
iors in the light/dark test are usually associated with
decreased plasma corticosterone levels [25]. On the con-
trary, in the laboratory and clinically, increased plasma
corticosterone/cortisol is associated with increased
depression-related and anxiety-like behaviors [17,21-
23,47-49]. However, the phenotypes of antidepressant-
like and less anxiety-related behaviors were associated
with increased corticosterone levels in PKCI/HINT1 KO
mice. This has an interesting parallel with clinical obser-
vations of increased plasma cortisol levels in manic
patients which was not an effect of stress but was
described as a feature of the disease [18]. Indeed, HPA axis
dysfunction was reported in bipolar disorder patients
[50,51] and in the mixed mania subtype of bipolar disor-
der patients [19]. In all cases, higher basal plasma cortisol
levels were found in bipolar patients relative to the con-
trols. Higher plasma cortisol levels in manic patients,
compared with healthy controls, were in the same propor-
tional range as what we observed in the PKCI/HINT1 mice
[18]. Moreover, in bipolar patients, the difference
occurred in the samples collected in the morning, which
corresponds to the awaking time [19,51]. This phenome-
non coincides with the findings in our mice. The differ-
ence in corticosterone levels between KO and WT mice
occurred during the window time that also corresponds to
awaking time in these nocturnal animals. When tested for
TST and FST in the morning between 9:00 to 10:00 am,
WT and PKCI/HINT1 KO mice displayed the same
amount of immobility time (data not shown).
The difference in plasma corticosterone levels should not
be attributed to a stress response due to handling since we
did not see any difference between WT and KO in the
morning samples. In WT mice, morning and afternoon
basal corticosterone levels were similar to those previ-
ously reported [21,52]. Moreover, WT and KO mice pre-
sented similar plasma corticosterone responses to the
acute stress of tail suspension. Those responses were in the
same range as the one described as the maximum
response to stress measured following a restraint stress in
mice,  ca  300 ng/ml [52]. Accordingly, the afternoon-
enhanced basal corticosterone levels may be considered
an endocrine feature specific to the phenotype of PKCI/
HINT1 KO mice.
Additionally, in KO mice, hyperactivity in the tail suspen-
sion test tended to be attenuated by acute treatment with
the clinically effective anti-mania drug valproic acid, sug-
gesting a facet of mania-like behavior. Therefore, the after-
noon behavioral and endocrine phenotypes of PKCI/
HINT1 KO mice could be analogous to mania symptoms
associated with high plasma cortisol [9,14,53-57]. In that
regard, enhanced performances in the place navigation
task and persistent struggling in the TST could be consid-
ered as enhanced goal-directed activity associated with
enhanced energy. Moreover these data are in consistent
with microarray results demonstrating a decrease in PKCI/
HINT1 expression in the brains of bipolar disorder
patients, making it a candidate molecule for the disease
[32]. Thus our results may suggest that the PKCI/HINT1
gene may be important in the neuropathology of mania.
Our speculations on our results are based on attempting
to draw parallels between our behavioral, endocrine and
pharmacological observations and clinical descriptions of
disease. One may argue that this extrapolation from mice
to human patients is excessive specifically because there is
no current valid rodent model for studying mania [58].
Further study of the function of PKCI/HINT1 in the nerv-
ous system could help in outlining a theoretical valida-
tion. Originally PKCI/HINT1 isolated from bovine brain
extracts was identified as an in vitro inhibitor of PKC iso-
forms [59] and PKC inhibitors are promising targets for
bipolar disorder drug development [60]. However, the
physiological significance of PKCI/HINT1's ability to
inhibit PKC has been questioned [59] and so far its exact
biochemical function is unclear. In our study, although
the exact role of PKCI/HINT1 in the development of those
combined phenotypes is unknown, some speculations
can be outlined based on the modulation by the protein
of the mu opioid receptor (MOPr). PKCI/HINT1 regulates
the MOPr by suppressing its desensitization and its PKC-
induced phosphorylation [61]. A deficiency in the expres-
sion of PKCI/HINT1 in mice can significantly enhance
both basal and morphine-induced analgesia [61,62].
Interestingly, in one study, manic patients exhibited
higher analgesia to experimentally-induced pain than
healthy matching controls [63]. Also, opioid analgesics
can precipitate a hypomanic/manic reaction in a signifi-
cant percentage of patients with bipolar disorder while
having an antidepressant effect in others [64]. In acutely
manic patients, methadone decreased symptoms of
euphoria, elation, and grandiosity, and significantly
decreased plasma cortisol levels. This implies a potentially
important interrelationship between the central endog-
enous opioid peptide systems, neuroendocrine regulatory
factors, and the pathophysiology of affective disorder
[65]. This could be linked to the effects of MOPr activity
on the HPA function in humans where stimulation of the
MOPr by the specific agonist fentanyl decreases the level
of plasma cortisol [66] and morning MOPr blockade by
naloxone induces an increase in ACTH and plasma corti-BMC Neuroscience 2009, 10:132 http://www.biomedcentral.com/1471-2202/10/132
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sol levels [67]. This could be a mechanism through which
changes in PKCI/HINT1 interactions with MOPr modu-
late MOPr-associated functions.
Conclusion
PKCI/HINT1 KO mice displayed a phenotype of behavio-
ral endocrine features indicative of changes of mood func-
tion, including anxiolytic-like, antidepressant-like
behaviors that tend to be blocked by the mood stabilizer
valproate, in conjunction with elevated levels of plasma
corticosterone. These results suggest that the PKCI/HINT 1
gene could be important for the mood regulation func-
tion in the CNS.
Methods
PKCI/HINT1 KO mice
The generation of PKCI/HINT1 KO mice was described
previously; 96% of the genetic background of these mice
and their WT littermates is from the 129SvJ strain [68]. In
the present study, KO and WT animals were derived from
heterozygous PKCI/HINT1 +/- breeding pairs. The geno-
type of all progeny was confirmed by PCR analysis of
DNA extracted from tail biopsies. Animals were housed 4-
5/cage and maintained under standard laboratory condi-
tions with food and water provided ad libitum. Male ani-
mals were tested between 6 to 9 months of age. Wild type
and PKCI/HINT1 KO groups were matched for age in all
experiments. Animals were submitted to a 12 hours dark/
light cycle with light on at 7:00 am, and experiments were
performed during the light phase. For each experiment,
animals were brought into the experimental room 30 min
prior to the experiment in order for them to acclimate to
the environment. Each experiment was performed inde-
pendently using a new group of animals. All studies were
conducted with a protocol approved by the University of
Maryland, School of Pharmacy IACUC, and studies con-
formed to the NIH Guidelines for the Care and Use of
Laboratory Animals.
Forced swim test
The test was based on the original version of the forced
swim test of Porsolt for mice [69] with modification; scor-
ing was performed in real time by observers unaware of
the genotype of the mice. Mice were placed in a 5 l cylin-
der (40 cm high, 25 cm diameter) filled with 3.5 l of
water, where they swam without the ability to touch the
bottom; water temperature was set at 30 ± 1°C to avoid
severe hypothermia [70]. The total time that the mice
spent immobile was measured, using a stopwatch. Immo-
bility was determined when the mouse was only making
movements necessary to keep its head above the water
and maintained a stationary posture; a stopwatch was
started within the first 2 sec immobility was observed. In
this posture forelimbs of the mouse are motionless and
directed forward, the tail is directed outward and the hind
legs are in limited motion. No animals showed difficulty
in swimming or in staying afloat. We used a 2 day proce-
dure as previously described [71]. On day 1, the mice were
placed in water to swim for a single trial of 15 min, and
immobility was recorded during the last 4 min of the trial.
Day 2 was aimed at assessing the learning and habituation
components of the repeated test. Mice were placed in
water through a series of four trials of 6 min each and
immobility was recorded during the last 4 min of each
trial. Each trial was followed by an 8 min rest period when
the animals were dried with towels and returned to their
cages; the water in the cylinder was changed between each
subject. Experiments were performed between 2:00 and
4:00 pm.
Tail suspension test
The automated tail suspension test (Med Associates, St
Albans VT) as previously described [72,73] was used to
assess antidepressant-like behavior. The haemodynamic
stress of being hung in an uncontrollable fashion by the
tail causes the animals to engage in three types of escape-
oriented movements: (1) running movements forward or
backwards; (2) body torsions with attempts to catch the
suspended body; and (3) body jerks followed temporally
by bouts of immobility [4,43]. A mouse is considered
immobile when it either hangs passively and completely
motionless, does not move its paws, or there is an absence
of initiated movements.
The automated device (Med Associates, St Albans VT) con-
sists of a box (box size: 32 × 33 × 33 cm) that is open on
the front side with a vertical aluminum bar (bar size: 11.5
× 2.2 × 0.15 cm), suspended from the top, connected to a
strain gauge that detects any movements from the mouse.
Mice were suspended by the tail and secured with a tape
for a 10 min test. The base of their tail was aligned with
the bottom of the bar. The total duration of immobility
was calculated as the time when the force of the mouse's
movements was below a preset lower threshold. An opti-
mal lower threshold was determined by comparing scores
of immobility rated manually with scores from the auto-
mated device in preliminary studies. Immobility was
defined as the absence of initiated movements and
included passive swaying. An upper threshold was deter-
mined in order to detect only vigorous movements. Thus
the following settings were used in all experiments: lower
threshold = 5, upper threshold = 50, gain = 4, time con-
stant = 0.25, resolution = 100 msec. The automatic equip-
ment monitored the duration of immobility as the time
below lower threshold. The vigor of activity was quanti-
fied as small movements, corresponding to running
movements and body torsions between lower and upper
threshold and strong movements of jerks and jumps rated
above the upper threshold.
Experiments were performed between 2:00 and 4:00 pm.BMC Neuroscience 2009, 10:132 http://www.biomedcentral.com/1471-2202/10/132
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Drug treatment
Valproic acid as sodium salt (Alexis Biochemicals, USA)
was prepared freshly in saline (NaCl 0.9%) and was
injected intraperitoneally (ip) at a volume of 10 ml/kg of
body weight, 30 min before the TST at doses of 100 mg/
kg or 300 mg/kg.
Light-dark test
The light-dark test to assess bright-space related anxiety
[74] was conducted in a dark-light insert consisting of two
compartments of same dimensions (13.95 cm × 27.9 cm)
separated with a transparent wall pierced with an open
door. The black compartment had opaque black walls and
roof while the lit compartment was entirely transparent to
light. The insert was placed into an open field chamber
equipped with 16 infra-red beams allowing tracking of the
animal position. The test was automated using activity
monitor software (Med Associates, St Albans VT). Mice
were placed in the box for a total time of 25 min; the
amount of time spent by the animal in each compartment
was monitored by 5 periods of 5 min each and reported in
seconds. The first 5 min bin was to assess anxiety-related
behavior while the remaining 20 min assessed putative
preference development. Experiments were performed
between 2:00 and 4:00 pm. Results are expressed as mean
± SEM of time spent in the lit compartment during each 5
min bin.
Morris water maze
The Morris water maze experiment consists of two tests:
cued learning [38] and place navigation using proximal
landmarks [39]. The two tests were performed independ-
ently using separate groups of animals. The maze con-
sisted of a 122 cm diameter circular pool of 25 cm height
sides filled with 25 ± 1°C water and made opaque with
milk. It was oriented in relation to the cardinal points, N,
S, E, W. The only mean of escape was through a circular
platform of 9 cm diameter and 11 cm height submerged
0.5 cm below the surface.
For the cued learning test, the platform was kept invisible
but was beacon cued with a striped ruler emerging at 12
cm above the surface of the water so that the mice could
locate it directly by sight. The test consisted of 4 trials of 2
min per day for 4 days. It assessed the animal's motivation
and ability to swim to escape from the aversive situation
of being placed into the water by associating the beacon-
cued platform with the escape. For each trial the platform
was located at the center of one of four quadrants NE, SE,
NW, SW; the mouse entered the pool, facing the wall,
from a different starting point each time so that the direct
route to the platform differed each time. Cued learning
was measured as the latency to reach the platform (sec).
Mice that failed to reach the platform within the 2 min
time limit were ascribed an escape latency of 120 sec and
guided to the platform. Mice were allowed to stay on the
platform for 5 sec before being dried with towels and
returned to their home cages.
To assess place navigation using proximal landmarks for
navigation, the pool was surrounded by white curtains to
isolate it from distal landmarks. Three unscalable objects
placed directly inside of the pool and emerging from the
surface of the water by 8 cm served as proximal landmarks
for the invisible platform. The objects were 500 ml square
bottles (side: 7 cm, height: 18 cm) filled up with white
sand. The bottles were distinguishable from each other by
the color of the caps (solid navy blue, white with black
stripes, or white with black dots) and by the pattern of the
protruding portion (white, white with black vertical
stripes, or white with black dots). The test started with an
initial session training consisting of 2 trials separated by
30 min interval; mice were placed on the platform for 15
sec to observe the landmarks prior to being put in the
water for 2 min. If the mouse did not find the platform
within the allotted time, it was guided to it and was
allowed to remain on it for 5 sec before being dried with
towels and returned to its home cage. The learning phase
started one day following the initial training. It consisted
of 4 trials of 2 min per day for 7 days; the interval between
each trial was at least 30 min. Before each trial both the
objects and the platform were rotated 120° with respect to
the center of the pool in a pseudorandom direction; mice
entered the pool, facing the wall, from different starting
positions that were randomly defined. Acquisition was
assessed through the latency to reach the platform (sec).
Mice that failed to reach the platform within the 2 min
time limit were ascribed an escape latency of 120 sec and
guided to the platform. Mice were allowed to stay on the
platform for 5 sec before being dried with towels and
returned to their home cages. One day following the last
acquisition trial, retention was evaluated in a probe trial
of 60 sec during which the platform was removed and the
number of times crossing the former platform area was
measured. For probe tests a leaden object the same dimen-
sion of the platform was placed on the bottom of the pool
to facilitate previous platform location. Trials were video
recorded using a digital camera placed above the pool.
Corticosterone level measurement
To determine plasmatic corticosterone levels in mice, 100
to 200 microliters of blood were collected from retro-
orbital bleeding (n = 15 mice in each group) into heparin
(1000 U/ml Sigma-Aldrich #H3393) pre-coated micro-
centrifuge tubes, centrifuged at 2500 × g for 5 min at room
temperature; the plasma supernatant was stored at -70°C
until corticosterone measurement. Corticosterone levels
were measured within 2 weeks following blood collection
by radioimmunoassay using a Corticosterone kit (MP Bio-
medical # 07120002) according to the instructions of theBMC Neuroscience 2009, 10:132 http://www.biomedcentral.com/1471-2202/10/132
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manufacturer. Morning and afternoon basal levels were
determined from blood collected in the morning 2 to 3
hours after light onset, between 9:00-10:00 am, and in the
afternoon 2 to 3 hours before the light was turned off,
between 4:00-5:00 pm. Plasma corticosterone levels fol-
lowing acute stress were also determined from blood col-
lected immediately after a 6 min tail suspension test
performed in the afternoon in the same time window of
4:00 to 5:00 pm.
Statistics
For all data, normality was assessed using the Kol-
mogorov-Smirnoff test. Scores of behavioral experiments
test were analyzed using a two way ANOVA and Bonfer-
roni post hoc test for comparison between groups when
significant (p < 0.05). Simple comparison between 2
groups was performed using Student's t-test for normal
groups and the Mann-Whitney test otherwise. For plasma
corticosterone levels, data were analyzed using a 2 way
ANOVA genotype × conditions, and a Bonferroni post hoc
test for comparison between groups when significant (p <
0.05). Results are represented as mean ± standard error of
the mean (SEM) in the figures. Analyses were performed
using Graphpad Prism version 4.00 for windows (Graph-
pad Software, San Diego, CA, USA).
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